At a glance
ClinicalIndex Comparison RecordN/ACompleted· 5 enrolled
Drug / intervention
PraxbindTMdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Surveillance Program of Praxbind Use in India.
In Brief
An observational study evaluating PraxbindTM for Thromboembolism. Completed, enrolled 5 participants across 3 sites.
Detailed Summary
This program will be initiated after the commercial availability of PraxbindTM in India. It will include patients administered with PraxbindTM into the surveillance program after commercial availability in 2 years at selected centres approved by the regulatory authority.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsThromboembolism
CountriesIndia
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartDec 2018
Primary CompletionJan 2020
TodayJul 2026
First PostedDec 2, 2017
Enrollment StartDec 26, 2018
Primary CompletionJan 13, 2020
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 8.6 years ago
Interventions
PraxbindTMdrug
Drug